JBC PeproTech; Our Business is Cytokines!

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M103652200 on August 14, 2001

J. Biol. Chem., Vol. 276, Issue 42, 38472-38479, October 19, 2001
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
276/42/38472    most recent
M103652200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shenk, J. L.
Right arrow Articles by Shemshedini, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shenk, J. L.
Right arrow Articles by Shemshedini, L.

p53 Represses Androgen-induced Transactivation of Prostate-specific Antigen by Disrupting hAR Amino- to Carboxyl-terminal Interaction*

Jennifer L. ShenkDagger §, Christopher J. FisherDagger , Shao-Yong Chen, Xiao-Feng Zhou, Karl Tillman, and Lirim Shemshedini||

From the Department of Biological Sciences, University of Toledo, Toledo, Ohio 43606

Prostate-specific antigen (PSA) is highly overexpressed in prostate cancer. One important regulator of PSA expression is the androgen receptor (AR), the nuclear receptor that mediates the biological actions of androgens. AR is able to up-regulate PSA expression by directly binding and activating the promoter of this gene. We provide evidence here that that this AR activity is repressed by the tumor suppressor protein p53. p53 appears to exert its inhibition of human AR (hAR) by disrupting its amino- to carboxyl-terminal (N-to-C) interaction, which is thought to be responsible for the homodimerization of this receptor. Consistent with this, p53 is also able to block hAR DNA binding in vitro. Our previous data have shown that c-Jun can mediate hAR transactivation, and this appears to result from a positive effect on hAR N-to-C interaction and DNA binding. Interestingly, c-Jun is able to relieve the negative effects of p53 on hAR transactivation, N-to-C interaction, and DNA binding, demonstrating antagonistic activities of these two proteins. Importantly, a p53 mutation found in metastatic prostate cancer severely disrupts the p53 negative activity on hAR, suggesting that the inability of p53 mutants to down-regulate hAR is, in part, responsible for the metastatic phenotype.

* This work was supported by a grant from the National Institutes of Health (to L. S.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Both authors contributed equally to this work.

§ Present address: Dept. of Molecular Endocrinology, Glaxo Smith Kline Research and Development, Research Triangle Park, NC 27709.

Present address: Dept. of Research, Beth Israel Deaconess Medical Center, Boston, MA 02215.

|| To whom correspondence should be addressed. Tel.: 419-530-1553; Fax: 419-530-7737; E-mail: lshemsh@uoft02.utoledo.edu.

Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.


This article has been cited by other articles:


Home page
 FASEB J.Home page
U. Moehren, M. Papaioannou, C. A. Reeb, A. Grasselli, S. Nanni, M. Asim, D. Roell, I. Prade, A. Farsetti, and A. Baniahmad
Wild-type but not mutant androgen receptor inhibits expression of the hTERT telomerase subunit: a novel role of AR mutation for prostate cancer development
FASEB J, April 1, 2008; 22(4): 1258 - 1267.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
H. V. Heemers and D. J. Tindall
Androgen Receptor (AR) Coregulators: A Diversity of Functions Converging on and Regulating the AR Transcriptional Complex
Endocr. Rev., December 1, 2007; 28(7): 778 - 808.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
C.-T. Wu, W.-C. Chen, S.-K. Liao, C.-L. Hsu, K.-D. Lee, and M.-F. Chen
The radiation response of hormone-resistant prostate cancer induced by long-term hormone therapy
Endocr. Relat. Cancer, September 1, 2007; 14(3): 633 - 643.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
N. K. Mukhopadhyay, B. Cinar, L. Mukhopadhyay, M. Lutchman, A. S. Ferdinand, J. Kim, L. W. K. Chung, R. M. Adam, S. K. Ray, A. B. Leiter, et al.
The Zinc Finger Protein Ras-Responsive Element Binding Protein-1 Is a Coregulator of the Androgen Receptor: Implications for the Role of the Ras Pathway in Enhancing Androgenic Signaling in Prostate Cancer
Mol. Endocrinol., September 1, 2007; 21(9): 2056 - 2070.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
C.-M. Chiu, S.-H. Yeh, P.-J. Chen, T.-J. Kuo, C.-J. Chang, P.-J. Chen, W.-J. Yang, and D.-S. Chen
Inaugural Article: Hepatitis B virus X protein enhances androgen receptor-responsive gene expression depending on androgen level
PNAS, February 20, 2007; 104(8): 2571 - 2578.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
C. J Burd, L. M Morey, and K. E Knudsen
Androgen receptor corepressors and prostate cancer
Endocr. Relat. Cancer, December 1, 2006; 13(4): 979 - 994.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. Sammons, S. S. Wan, N. L. Vogel, E. J. Mientjes, G. Grosveld, and B. P. Ashburner
Negative Regulation of the RelA/p65 Transactivation Function by the Product of the DEK Proto-oncogene
J. Biol. Chem., September 15, 2006; 281(37): 26802 - 26812.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Z. Zheng, C. Cai, J. Omwancha, S.-Y. Chen, T. Baslan, and L. Shemshedini
SUMO-3 Enhances Androgen Receptor Transcriptional Activity through a Sumoylation-independent Mechanism in Prostate Cancer Cells
J. Biol. Chem., February 17, 2006; 281(7): 4002 - 4012.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
A. Kirschenbaum, X.-H. Liu, S. Yao, G. Narla, S. L. Friedman, J. A. Martignetti, and A. C. Levine
Sex steroids have differential effects on growth and gene expression in primary human prostatic epithelial cell cultures derived from the peripheral versus transition zones
Carcinogenesis, February 1, 2006; 27(2): 216 - 224.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
C. J. Burd, C. E. Petre, H. Moghadam, E. M. Wilson, and K. E. Knudsen
Cyclin D1 Binding to the Androgen Receptor (AR) NH2-Terminal Domain Inhibits Activation Function 2 Association and Reveals Dual Roles for AR Corepression
Mol. Endocrinol., March 1, 2005; 19(3): 607 - 620.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
D.-Y. Lin, H.-I Fang, A.-H. Ma, Y.-S. Huang, Y.-S. Pu, G. Jenster, H.-J. Kung, and H.-M. Shih
Negative Modulation of Androgen Receptor Transcriptional Activity by Daxx
Mol. Cell. Biol., December 15, 2004; 24(24): 10529 - 10541.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
M. Powzaniuk, S. McElwee-Witmer, R. L. Vogel, T. Hayami, S. J. Rutledge, F. Chen, S.-i. Harada, A. Schmidt, G. A. Rodan, L. P. Freedman, et al.
The LATS2/KPM Tumor Suppressor Is a Negative Regulator of the Androgen Receptor
Mol. Endocrinol., August 1, 2004; 18(8): 2011 - 2023.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
P. V. Nantermet, J. Xu, Y. Yu, P. Hodor, D. Holder, S. Adamski, M. A. Gentile, D. B. Kimmel, S.-i. Harada, D. Gerhold, et al.
Identification of Genetic Pathways Activated by the Androgen Receptor during the Induction of Proliferation in the Ventral Prostate Gland
J. Biol. Chem., January 9, 2004; 279(2): 1310 - 1322.
[Abstract] [Full Text] [PDF]

Home page
 Mol Hum ReprodHome page
W.A. Schulz, M. Burchardt, and M.V. Cronauer
Molecular biology of prostate cancer
Mol. Hum. Reprod., August 1, 2003; 9(8): 437 - 448.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Y.-H. Wang, Y.-G. Tsay, B. C.-M. Tan, W.-Y. Lo, and S.-C. Lee
Identification and Characterization of a Novel p300-mediated p53 Acetylation Site, Lysine 305
J. Biol. Chem., July 3, 2003; 278(28): 25568 - 25576.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. J. Nesslinger, X.-B. Shi, and R. W. deVere White
Androgen-independent Growth of LNCaP Prostate Cancer Cells Is Mediated by Gain-of-Function Mutant p53
Cancer Res., May 1, 2003; 63(9): 2228 - 2233.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
C. J. Loy, K. S. Sim, and E. L. Yong
Filamin-A fragment localizes to the nucleus to regulate androgen receptor and coactivator functions
PNAS, April 15, 2003; 100(8): 4562 - 4567.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. Bubulya, S.-Y. Chen, C. J. Fisher, Z. Zheng, X.-Q. Shen, and L. Shemshedini
c-Jun Potentiates the Functional Interaction between the Amino and Carboxyl Termini of the Androgen Receptor
J. Biol. Chem., November 21, 2001; 276(48): 44704 - 44711.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2001 by the American Society for Biochemistry and Molecular Biology.